These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 19026356)

  • 1. Racial differences in erythropoietin responsiveness.
    Kaufman JS
    Am J Kidney Dis; 2008 Dec; 52(6):1035-8. PubMed ID: 19026356
    [No Abstract]   [Full Text] [Related]  

  • 2. Should all patients with chronic kidney disease receive an EPO-type drug?
    Berns JS
    Cleve Clin J Med; 2006 Mar; 73(3):298-300. PubMed ID: 16548453
    [No Abstract]   [Full Text] [Related]  

  • 3. Anemia in chronic kidney disease: causes, diagnosis, treatment.
    Nurko S
    Cleve Clin J Med; 2006 Mar; 73(3):289-97. PubMed ID: 16548452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Racial variations in erythropoietic response to epoetin alfa in chronic kidney disease and the impact of smoking.
    Jones-Burton C; Seliger SL; Brown J; Stackiewicz L; Hsu VD; Fink JC
    Nephrol Dial Transplant; 2005 Dec; 20(12):2739-45. PubMed ID: 16188897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regarding impact of epoetin alfa on clinical end points in patients with chronic renal failure: a meta-analysis.
    Tonelli M; Owen WF; Jindal K; Winkelmayer WC; Manns B
    Kidney Int; 2004 Oct; 66(4):1712; author reply 1712-3. PubMed ID: 15458473
    [No Abstract]   [Full Text] [Related]  

  • 6. [Epoetin alfa: recent strategies of use].
    Tumori; 1997; 83(6):975-8. PubMed ID: 9537918
    [No Abstract]   [Full Text] [Related]  

  • 7. Focus on epoetin: key findings of mini-sessions.
    Semin Oncol; 1998 Jun; 25(3 Suppl 7):69-75. PubMed ID: 9671335
    [No Abstract]   [Full Text] [Related]  

  • 8. Effects of Epoetin alfa on hemostasis in chronic renal failure.
    Tang WW; Stead RA; Goodkin DA
    Am J Nephrol; 1998; 18(4):263-73. PubMed ID: 9653828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anemia management in chronic kidney disease: role of factors affecting epoetin responsiveness.
    Eschbach JW
    J Am Soc Nephrol; 2002 May; 13(5):1412-4. PubMed ID: 11961032
    [No Abstract]   [Full Text] [Related]  

  • 10. Use of epoetin in chronic renal failure.
    Coyne DW
    JAMA; 2007 Apr; 297(15):1713-6. PubMed ID: 17440149
    [No Abstract]   [Full Text] [Related]  

  • 11. Cancer-related anaemia requires higher doses of epoetin alfa than chronic renal failure replacement therapy.
    Itri LM
    Nephrol Dial Transplant; 2001 Dec; 16(12):2289-93. PubMed ID: 11733616
    [No Abstract]   [Full Text] [Related]  

  • 12. Epoetin alfa for treatment of anemia in HIV-infected patients: past, present, and future.
    Henry DH; Volberding PA; Leitz G
    J Acquir Immune Defic Syndr; 2004 Oct; 37(2):1221-7. PubMed ID: 15385728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting the hematopoietic response to recombinant human erythropoietin (Epoetin alfa) in the treatment of the anemia of cancer.
    Adamson JW; Ludwig H
    Oncology; 1999; 56(1):46-53. PubMed ID: 9885377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of Carnitor for Epogen resistant anemia.
    Simard JC
    ANNA J; 1999 Feb; 26(1):41-2. PubMed ID: 10222857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does TREAT give the boot to ESAs in the treatment of CKD anemia?
    Singh AK
    J Am Soc Nephrol; 2010 Jan; 21(1):2-6. PubMed ID: 20035034
    [No Abstract]   [Full Text] [Related]  

  • 16. Epoetin dosing and dialysis facility ownership.
    Regidor DL; Kalantar-Zadeh K; Kovesdy CP
    JAMA; 2007 Aug; 298(8):862; author reply 862-3. PubMed ID: 17712068
    [No Abstract]   [Full Text] [Related]  

  • 17. Epoetin dosing and dialysis facility ownership.
    Kliger AS; Nissenson AR
    JAMA; 2007 Aug; 298(8):861-2; author reply 862-3. PubMed ID: 17712067
    [No Abstract]   [Full Text] [Related]  

  • 18. Improvement in quality of life for cancer patients treated with epoetin alfa.
    Libretto SE; Barrett-Lee PJ; Branson K; Gorst DW; Kaczmarski R; McAdam K; Stevenson P; Thomas R
    Eur J Cancer Care (Engl); 2001 Sep; 10(3):183-91. PubMed ID: 11829381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential mechanisms of adverse outcomes in trials of anemia correction with erythropoietin in chronic kidney disease.
    Vaziri ND; Zhou XJ
    Nephrol Dial Transplant; 2009 Apr; 24(4):1082-8. PubMed ID: 18987263
    [No Abstract]   [Full Text] [Related]  

  • 20. Erythropoietin stimulating agents and epoetin alfa revisited: what's really relevant?
    Walker RG
    Clin J Am Soc Nephrol; 2008 Jul; 3(4):935-7. PubMed ID: 18579671
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.